Methylprednisolone hemisuccinate

Generic Name: Methylprednisolone hemisuccinate

Brand Names: Solu-medrol

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₄O_₈

CAS Number: 2921-57-5

Unique Ingredient Identifier: 5GMR90S4KN

Background: A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.

Associated Conditions: Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis

Associated Therapies: Palliative Treatment

Clinical Trials

Randomized Trial for Mixed Acute Rejection

Phase 2

Completed

Conditions: Graft Rejection

Interventions: Drug: Rabbit Antithymocyte Globulin (RATG)
Drug: Rituximab
Drug: Antihistamine
Drug: Bortezomib
Drug: Acetaminophen
Drug: Methylprednisolone

First Posted Date: 2008-10-15

Last Posted Date: 2016-01-27

Lead Sponsor: University of Cincinnati

Target Recruit Count: 30

Registration Number: NCT00771875

Locations: 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
🇺🇸
The Christ Hospital, Cincinnati, Ohio, United States

Chronotherapy in Acute Multiple Sclerosis (MS) Attack

Not Applicable

Terminated

Conditions: Multiple Sclerosis

Interventions: Drug: methylprednisolone
Drug: Sodium chlorid

First Posted Date: 2008-10-02

Last Posted Date: 2014-11-24

Lead Sponsor: Sykehuset Innlandet HF

Target Recruit Count: 57

Registration Number: NCT00764413

Locations: 🇳🇴
Innlandet Hosptal Trust-Lillehammer, Neurological Department, Lillehammer, Oppland, Norway

Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse

Phase 4

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: methylprednisolone
Drug: Placebo

First Posted Date: 2008-09-17

Last Posted Date: 2011-06-02

Lead Sponsor: Germans Trias i Pujol Hospital

Target Recruit Count: 49

Registration Number: NCT00753792

Locations: 🇪🇸
Hospital de Mataró, Barcelona, Spain
🇪🇸
Hospital Clinic de Barcelona, Barcelona, Spain
🇪🇸
Hospital Vall d'Hebron, Barcelona, Spain

and more 4 locations

Anti-Cytokine Therapy for Vasculitis

Phase 2

Completed

Conditions: Wegener's Granulomatosis
Renal Limited Vasculitis
Microscopic Polyangiitis

Interventions: Biological: Infliximab
Drug: Cyclophosphamide
Drug: Prednisolone
Drug: Azathioprine
Procedure: Plasma exchange
Drug: Mycophenolate mofetil
Drug: Methylprednisolone

First Posted Date: 2008-09-16

Last Posted Date: 2008-09-16

Lead Sponsor: University Hospital Birmingham NHS Foundation Trust

Target Recruit Count: 37

Registration Number: NCT00753103

Locations: 🇬🇧
University Hospitals Birmingham NHS Foundation Trust, Birmingham, West Midlands, United Kingdom

A 3-arm Multi-center, Randomized Controlled Study Comparing Transforaminal Corticosteroid, Transforaminal Etanercept and Transforaminal Saline for Lumbosacral Radiculopathy

Phase 2

Completed

Conditions: Lumbosacral Radiculopathy

Interventions: Drug: etanercept
Drug: normal saline
Drug: methylprednisolone

First Posted Date: 2008-08-12

Last Posted Date: 2012-10-08

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 84

Registration Number: NCT00733096

Locations: 🇺🇸
Walter Reed Army Medical Center, Washington, District of Columbia, United States
🇺🇸
Womack Army Medical Center, Fort Bragg, North Carolina, United States

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Methylprednisolone
Drug: Etoposide
Drug: Cytarabine
Drug: Cisplatin
Drug: Rituximab
Drug: In-Zevalin
Drug: Y-Zevalin

First Posted Date: 2008-08-12

Last Posted Date: 2019-09-04

Lead Sponsor: University of Arizona

Target Recruit Count: 28

Registration Number: NCT00732498

Locations: 🇺🇸
The University of Arizona Cancer Center, Tucson, Arizona, United States

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

First Posted Date: 2008-07-22

Last Posted Date: 2020-04-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 63

Registration Number: NCT00720109

Locations: 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Valley Children's Hospital, Madera, California, United States

and more 131 locations

Corticosteroids for Cancer Pain

Phase 3

Completed

Conditions: Pain
Cancer

Interventions: Drug: Placebo
Drug: Methylprednisolone

First Posted Date: 2008-05-13

Last Posted Date: 2020-09-01

Lead Sponsor: Norwegian University of Science and Technology

Target Recruit Count: 50

Registration Number: NCT00676936

Locations: 🇳🇴
Haraldsplass Diakonale sykehus, Bergen, Norway
🇳🇴
Sørlandet Sykehus HF, Kristiansand, Norway
🇳🇴
Sykehuset Telemark HF, Skien, Norway

and more 3 locations